- Trials with a EudraCT protocol (148)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
148 result(s) found for: Central pain syndrome.
Displaying page 1 of 8.
EudraCT Number: 2010-024265-40 | Sponsor Protocol Number: KETA-FAN | Start Date*: 2011-10-27 | |||||||||||
Sponsor Name:HOSPITAL UNIVERSITARI DE BELLVITGE | |||||||||||||
Full Title: Perineural vs systemic N-methyl-D-aspartate (NMDA) receptors antagonism with ketamine as a reverser of peripheral and central sensitization in phantom limb pain | |||||||||||||
Medical condition: Phantom limb pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-008339-27 | Sponsor Protocol Number: A0081107 | Start Date*: 2009-05-07 | |||||||||||
Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY10017 | |||||||||||||
Full Title: A 17-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, MULTI-CENTER TRIAL OF PREGABALIN FOR THE TREATMENT OF CHRONIC CENTRAL NEUROPATHIC PAIN AFTER SPINAL CORD INJURY | |||||||||||||
Medical condition: Chronic Central Neuropathic Pain after Spinal Cord Injury. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000473-25 | Sponsor Protocol Number: ESKEFIB | Start Date*: 2020-06-30 |
Sponsor Name:Grand Hôpital de Charleroi | ||
Full Title: ESKETamine for FIBromyalgia treatment | ||
Medical condition: Patients diagnosed with a fibromyalgia syndrome as established by the 2016 ACR criteria and presenting criteria of central sensitization syndrome (based of the CSI (CSI>40)). | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2007-003230-42 | Sponsor Protocol Number: F13640GE210 | Start Date*: 2007-10-08 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Study of the analgesic effects of repeated doses of F13640 in spinal cord injury patients with moderate to severe central neuropathic pain. A multinational, multicenter, randomized, double blind, p... | |||||||||||||
Medical condition: Central neuropathic pain due to spinal cord injury, based on clinical history, clinical examination and appropriate assessment of patient’s signs and symptoms, according to the International Associ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) FI (Prematurely Ended) ES (Completed) BE (Completed) IT (Prematurely Ended) NL (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003972-21 | Sponsor Protocol Number: DS5565-A-U307 | Start Date*: 2015-09-10 | |||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED SAFETY STUDY OF DS-5565 FOR TREATMENT OF PAIN DUE TO FIBROMYALGIA IN SUBJECTS WITH CHRONIC KIDNEY DISEASE | |||||||||||||
Medical condition: DS-5565 is being investigated for the treatment of pain associated with fibromyalgia (FM) in subjects with chronic kidney disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002943-11 | Sponsor Protocol Number: KF5503/60 | Start Date*: 2013-02-25 | ||||||||||||||||
Sponsor Name:Grünenthal GmbH | ||||||||||||||||||
Full Title: Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus oxycodone/naloxone PR in non-opioid pre-treated subjects with uncontrolled severe chronic low back pain with a neur... | ||||||||||||||||||
Medical condition: Severe chronic low back pain with a neuropathic pain component | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) IT (Completed) AT (Completed) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004812-73 | Sponsor Protocol Number: BP18-1-501 | Start Date*: 2022-05-16 |
Sponsor Name:Leiden University | ||
Full Title: The influence of pharmacological conditioning with S-ketamine on pain sensitivity in patients with Fibromyalgia Syndrome | ||
Medical condition: Fibromyalgia Syndrome | ||
Disease: | ||
Population Age: Adults | Gender: Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2019-004943-54 | Sponsor Protocol Number: STA-02 | Start Date*: 2020-06-15 | |||||||||||
Sponsor Name:Stayble Therapeutics AB | |||||||||||||
Full Title: A multi-country, randomized, double-blind, placebo-controlled study investigating the efficacy and safety of STA363 at two concentrations (60 mg/mL and 120 mg/mL) compared to placebo in patients wi... | |||||||||||||
Medical condition: Сhronic discogenic low back pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-019998-14 | Sponsor Protocol Number: KF5503/58 | Start Date*: 2011-02-15 | ||||||||||||||||
Sponsor Name:Grünenthal GmbH | ||||||||||||||||||
Full Title: Evaluation of the effectiveness, safety, and tolerability of tapentadol PR versus a combination of tapentadol PR and pregabalin in subjects with severe chronic low back pain with a neuropathic pain... | ||||||||||||||||||
Medical condition: severe chronic low back pain with a neuropathic pain component | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) DE (Completed) AT (Completed) BE (Completed) ES (Completed) DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-003137-40 | Sponsor Protocol Number: F02207GE302 | Start Date*: 2015-09-28 |
Sponsor Name:Pierre Fabre Medicament | ||
Full Title: A European Phase III, Multicentre, Double-blind, Randomised, Placebo-Controlled Monotherapy Study of Milnacipran for the Treatment of the Fibromyalgia Syndrome. | ||
Medical condition: Fibromyalgia, also known as FMS, is a common systemic rheumatologic disorder estimated to affect 2 to 4% of the population Fibromyalgia is associated with a reduced threshold for pain, generally i... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) FI (Completed) SE (Completed) ES (Completed) PT (Completed) DE (Completed) GB (Completed) CZ (Completed) IT (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000347-28 | Sponsor Protocol Number: KF10004/10 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:Grünenthal GmbH | |||||||||||||
Full Title: Efficacy and safety of lidocaine 5% medicated plaster in localized chronic post-operative neuropathic pain | |||||||||||||
Medical condition: moderate to severe localized chronic post-operative neuropathic pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) AT (Completed) ES (Completed) IT (Completed) DK (Completed) FR (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-001587-30 | Sponsor Protocol Number: GU11SU387 | Start Date*: 2013-09-26 | ||||||||||||||||
Sponsor Name:NHS Greater Glasgow and Clyde | ||||||||||||||||||
Full Title: The role of pre-emptive analgesia with Qutenza (topical capsaicin 8%) in preventing neuropathic pain following lower limb amputation: a pilot randomised controlled study | ||||||||||||||||||
Medical condition: Chronic neuropathic pain following limb amputation | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003925-23 | Sponsor Protocol Number: PIANISSIMO | Start Date*: 2023-04-12 |
Sponsor Name:Vrije Universiteit Brussel | ||
Full Title: Pain medication tapering for patients with Persistent Spinal Pain Syndrome Type II, treated with Spinal Cord Stimulation. | ||
Medical condition: Persistent spinal pain syndrome type 2 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2009-015619-42 | Sponsor Protocol Number: XPF-001-202 | Start Date*: 2010-02-09 | |||||||||||
Sponsor Name:Xenon Pharmaceuticals Inc. | |||||||||||||
Full Title: Phase 2a, Single-Blind, Placebo-Controlled, 3-Period, 2-Treatment, Crossover Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Multiple Oral Doses of XPF-001 in Patients with Inherited... | |||||||||||||
Medical condition: Inherited erythromelalgia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004503-39 | Sponsor Protocol Number: IG1104 | Start Date*: 2015-01-28 | ||||||||||||||||
Sponsor Name:Instituto Grifols, S.A. | ||||||||||||||||||
Full Title: A multicenter, prospective, randomized, placebo-controlled, double-blind, parallel-group clinical trial to assess the efficacy and safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF... | ||||||||||||||||||
Medical condition: Patients with Post-polio syndrome | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) DE (Prematurely Ended) DK (Prematurely Ended) NL (Completed) ES (Prematurely Ended) PL (Prematurely Ended) RO (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-002608-42 | Sponsor Protocol Number: PD0004 | Start Date*: 2013-01-10 | |||||||||||
Sponsor Name:UCB Biosciences GmbH | |||||||||||||
Full Title: A Multicenter, Multinational, Double-blind, Placebo-controlled, 2-arm Study to Evaluate the Efficacy of Rotigotine on Parkinson's Disease-Associated Pain | |||||||||||||
Medical condition: Parkinson’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) GB (Completed) HU (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003770-14 | Sponsor Protocol Number: 3030-202-002 | Start Date*: 2018-10-11 | ||||||||||||||||
Sponsor Name:Allergan LTD | ||||||||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients (Age 12 to 17 Years) with Irrit... | ||||||||||||||||||
Medical condition: Irritable Bowel Syndrome with Diarrhea (IBS-D) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) HU (Completed) NL (Completed) DE (Prematurely Ended) PL (Completed) BG (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003490-15 | Sponsor Protocol Number: CACZ885D2308 | Start Date*: 2016-04-14 | ||||||||||||||||||||||||||
Sponsor Name:Novartis Pharmaceuticals | ||||||||||||||||||||||||||||
Full Title: An Open-label, Efficacy and Safety Study of Canakinumab (Anti-interleukin-1β Monoclonal Antibody) Administered for 6 Months (24 Weeks) in Japanese Patients With the Following Cryopyrin-associated P... | ||||||||||||||||||||||||||||
Medical condition: Cryopyrin-associated Periodic Syndromes Familial Cold Autoinflammatory Syndrome Muckle-Wells Syndrome Neonatal Onset Multisystem Inflammatory Disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-003558-34 | Sponsor Protocol Number: GS-US-445-4189 | Start Date*: 2017-07-03 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Phase 2, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Filgotinib, GS-9876 and GS-4059 in Adult Subjects with Active Sjogren’s Syndrome | |||||||||||||
Medical condition: Active Sjogren’s Syndrome | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011009-18 | Sponsor Protocol Number: ALO-FC-001 | Start Date*: 2009-04-20 | ||||||||||||||||||||||||||
Sponsor Name:AZIENDA OSPEDALIERO UNIVERSITARIA DI CAGLIARI | ||||||||||||||||||||||||||||
Full Title: Pilot study on the efficacy of IV haloperidol in the treatment of chronic migraine with and without medication overuse | ||||||||||||||||||||||||||||
Medical condition: Chronic migraine with and without medication overuse | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: IT (Prematurely Ended) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
